İbrahim AKTAŞ, Ahmet TÜTÜNCÜ, Mehmet MELEK, Hasan ARI, Selma ARI, Alper KARAKUŞ, Sencer CAMCİ

The effect of levosimendan on Tp-e interval, Tp-e/QT ratio, Tp-e/QTc ratio and QRS interval in heart failure patients

Increased Tp-e interval (from the peak-to-the-end of the electrocardiographic T wave) and Tp- e/QT ratio are associated with malignant ventricular arrhythmias. We aimed to evaluate the acute effects of levosimendan on Tp-e interval, Tp-e/QT ratio, Tp-e/QTc ratio and QRS interval in patients with severe heart failure. Methods. The study included 85 patients with decompansed heart failure, who were treated with levosimendan in our cardiology department . We evaluated the patients retrospectively. QT and Tp-e interval were assessed in the precordial leads. QRS duration was determined in the single lead which had the longest QRS. Electrocardiographic measurements was performed the basal (just before the levosimendan) and 24th hour after the levosimendan infusion (just after the levosimendan infusion). Results. No significant differences were found between before and after treatment of levosimendan with respect to Tp-e and QTc interval, QRS duration, Tp-e/QT and Tp-e/QTc ratio (pretreatment versus 24th hour values; p>0.05). Subgroup analysis was performed in the patients with inotropic therapy including dopamine and/or dobutamin (34 patients) and without inotropic therapy (49 patients) during the levosimendan infusion. The analysis showed that pretreatment and 24th hour values of Tp-e interval and Tp-e/QT ratio were significantly higher in the inotropic therapy group; (Pretreatment; Tp-e: 100.12±22.96 milliseconds [ms] versus 89.59±17.67 ms; p=0.03, Tp-e/QT: 0.26±0.05 versus 0.23±0.04; p=0.007, 24th hour: Tp-e: 101.41±27.09 ms versus 88.77±15.89 ms; p=0.009, Tp-e/QT: 0.26±0.07 versus 0.23±0.05; p=0.03). However intra-group changes of these parameters, before and after levosimendan treatment , were not significant (p>0.05). Conclusion. Our results suggested that, therapeutic doses of levosimendan infusion don’t have a significant effect on Tp-e and Tp-e/QT parameters. However inotropic therapy significantly increases these parameters.

PDF

___

[1] Gupta P, Patel C, Patel H, Narayanaswamy S, Malhotra B, Green JT, et al. Tp-e/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008;41:567-74.
[2] Kors JA, van Eck HJR, van Herpen G. The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol 2008;41:575-80.
[3] Endoh M. The therapeutic potential of novel cardiotonic agents. Expert Opin Investig Drugs 2003;12:735-50.
[4] Kass DA, Solaro RJ. Mechanisms and use of calcium- sensitizing agents in the failing heart. Circulation 2006;113:305-15.
[5] Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 2005;6:2741-51.
[6] Singh BN, Lilleberg J, Sandell E-P, Ylonen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 1999;83:16-20.
[7] Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions 2005. Dallas, Texas Late Breaking Clinical Trials II 2005.
[8] Ozlem F, Yilmaz M, Topal D, Tenekecioglu E, Kanat S, Vatansever F, et al. Evaluation of Tp-e interval and Tp-e/ QTc ratio in patients with mild to moderate psoriasis. Eur Res J 2016;2:46-51.
[9] Moiseyev V, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo- controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.
[10] Eris C, Yavuz S, Toktas F, Turk T, Gucu A, Erdolu B, et al. Preoperative usages of levosimendan in patients undergoing coronary artery bypass grafting. Int J Clin Exp Med 2014;7:219- 29.
[11] Follath F, Cleland J, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
[12] Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006;98:1641-5.
[13] Lilleberg J, Ylönen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scandinavian Cardiovasc J 2004;38:80-4.
[14] Tek M, Cavusoglu Y, Demirustu C, Birdane A, Unalir A, Gorenek B, et al. Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure. Turk Kardiyol Dern Ars 2010;38:334-40.
[15] Yontar OC, Yilmaz MB, Yalta K, Erdem A, Tandogan I. Acute effects of levosimendan and dobutamine on QRS duration in patients with heart failure. Arq Bras Cardiol 2010;95:738-42.
[16] Paksoy F, Ulas T, Tursun I, Dal MS, Oztekin E, Borlu F. The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study. Anadolu Kardiyol Derg 2012;12:16-22.